Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 556 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: no Condition Clear all
Terminated Phase 3 Interventional Results available

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

NCT04729387
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Alpelisib, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Terminated Phase 2 Interventional

A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

NCT00494663
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
DIO-902, DIO-902 placebo
Drug
Lead sponsor
DiObex
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2008 · Synced Oct 28, 2026, 12:20 PM EDT
Not yet recruiting Not applicable Interventional

Neuromodulation to Overcome Severe Restless Legs Syndrome

NCT07780032
View directory record Official record
Conditions
Restless Leg Syndrome (RLS), Spinal Cord Stimulation (SCS)
Interventions
Spinal Cord Stimulation
Device
Lead sponsor
Marshall Holland
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Withdrawn No phase listed Observational

Staged Bilateral Carpal Tunnel Release: Which Side Hurts More?

NCT02198521
View directory record Official record
Conditions
Carpal Tunnel Syndrome, Pain
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Not applicable Interventional Results available

Cranial Electrotherapy Stimulation (CES) Therapy

NCT02453347
View directory record Official record
Conditions
TBI, Anxiety, PTSD, Depression
Interventions
CES Therapy
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

NCT02622321
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, rFVIIa, aPCC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 28, 2026, 12:20 PM EDT
Recruiting Not applicable Interventional

The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

NCT06433011
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
The Bashir™ Endovascular Catheter, r-tPA
Device · Drug
Lead sponsor
Thrombolex, Inc.
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Scottsdale, Arizona • Tuscon, Arizona • Lakeland, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Not applicable Interventional

Set Your Goal: Engaging Go/No-Go Active Learning

NCT03538535
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Go/No-Go Active Learning (GOAL)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 28, 2026, 12:20 PM EDT
Active, not recruiting Phase 2 Interventional

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

NCT04443348
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Biopsy-proven, Positive Lymph Node(s)
Interventions
Radiation Therapy Boost, Pembrolizumab, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine
Radiation · Drug
Lead sponsor
Laura M. Spring, MD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Phase 1 Interventional

Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma

NCT00978523
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
Drug
Lead sponsor
Arno Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Scottsdale, Arizona • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 28, 2026, 12:20 PM EDT
Recruiting Phase 4 Interventional

Comparing Intravitreal Injection Pain Scores Using Iheezo (Chloroprocaine Hcl Ophthalmic Gel 3%) Versus Subconjunctival Lidocaine (2%): A Randomized, Controlled Trial

NCT07895420
View directory record Official record
Conditions
No Condition
Interventions
chloroprocaine HCL 3%, Subconjunctival Lidocaine
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Glen Carbon, Illinois • Chesterfield, Missouri • City of Saint Peters, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Infant and Parent Shared Book Reading

NCT04337372
View directory record Official record
Conditions
Individual, Category, and No-label Conditions
Interventions
Effects of shared book reading: Labels
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
5 Months to 65 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Phase 4 Interventional Results available

A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

NCT00145795
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra + Current Dual NRTI Backbone, Current Regimen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 28, 2026, 12:20 PM EDT
Recruiting Phase 3 Interventional

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2039
U.S. locations
281
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Dublin, California + 224 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Perceptions of Aesthetic Outcomes of Zigzag and Linear Scars

NCT02115789
View directory record Official record
Conditions
Linear Scar, Zigzag Scar
Interventions
Visual Analog Scale
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
876 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 28, 2026, 12:20 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis

NCT00854750
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACTHAR
Drug
Lead sponsor
Elliot Frohman
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 28, 2026, 12:20 PM EDT
Completed No phase listed Observational

Early Diagnosis of Steroid-Responsive & No-Responsive Hearing Loss

NCT00013468
View directory record Official record
Conditions
Hearing Loss
Interventions
Tinnitus
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Not applicable Interventional

Aerosols in the Treatment of Asymptomatic Pneumocystis Pneumonia: A Pilot Study Assessing the Effectiveness of Aerosolized Pentamidine as Treatment of Subclinical Pneumocystis Infection in Patients With No Clinical Symptoms

NCT00000707
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 28, 2026, 12:20 PM EDT
Withdrawn Not applicable Interventional

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

NCT01770600
View directory record Official record
Conditions
Impulsivity, Active Suicidal Ideation, Depression
Interventions
placebo, Riperidone
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 28, 2026, 12:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

NCT04774718
View directory record Official record
Conditions
ALK Fusion-positive Solid or CNS Tumors
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
7
States / cities
Palo Alto, California • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Not applicable Interventional

Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction

NCT01734980
View directory record Official record
Conditions
Mediastinal Lymphadenopathy, Lung Malignancies
Interventions
Endobronchial Ultrasound
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Oct 28, 2026, 12:20 PM EDT
Completed Phase 2 Interventional Results available

Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug

NCT04534114
View directory record Official record
Conditions
End Stage Renal Disease Requiring Hemodialysis
Interventions
Fesomersen sodium (BAY2976217), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 28, 2026, 12:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Triton Agreement and Precision Study

NCT03080714
View directory record Official record
Conditions
Healthy Eyes, Eye Diseases
Interventions
Topcon DRI OCT Triton (plus), 3D OCT-1 Maestro
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Willmar, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 28, 2026, 12:20 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Anastrozole, Letrozole, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
20
States / cities
Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 28, 2026, 12:20 PM EDT